News | January 17, 2024
Parexel collaborates with Japanese Foundation for cancer research
Collaboration streamlines patient access to oncology clinical trials
Collaboration streamlines patient access to oncology clinical trials
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Comprehensive clinical development programs being initiated for each investigational candidate
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Subscribe To Our Newsletter & Stay Updated
